J&J's Abiomed Wins Key Heart-Pump Patent Trial, Patent Declared Invalid
JNJ sits 55% above its 52-week low of $149.04 on light trading volume (0.2× avg).
Summary
Johnson & Johnson's Abiomed subsidiary secured a significant legal victory, defeating patent infringement claims in a US trial concerning its Impella heart pumps. The jury not only found no infringement but also declared the patent invalid, removing a substantial legal overhang. This is a positive development for a product line that generated $1.75 billion in 2025 revenue and was part of J&J's $16.6 billion acquisition of Abiomed. This win comes amidst J&J's ongoing navigation of various legal challenges, as seen in recent court decisions. A second related patent lawsuit against Abiomed remains ongoing.
At the time of this announcement, JNJ was trading at $230.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $555.5B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.